Novozymes A/S Q1 2026 Earnings Recap

Novonesis shares declined 2.7% following Q1 results that showed margin pressure in key divisions and cautious volume-driven growth amid headwinds, falling short of fully reassuring investors despite stable guidance.

Key Takeaways

• Organic sales grew 7% overall, including a 1.5 percentage point drag from exiting certain countries and a 1 point boost from inventory buildup in Animal.
• Adjusted EBITDA margin was 37.8%, slightly below the maintained full-year guidance range of 37–38%, indicating margin compression primarily from product mix shifts and currency impact.
• Food & Health Biosolutions grew 9% organically but saw a 130 basis point margin decline driven by commercial ramp-up, unfavorable product mix (notably HMO), and currency headwinds.
• Food & Beverages posted 11% volume-driven organic growth with pricing contributing ~1 point; growth was broad-based but reliant on innovation adoption amid muted consumer sentiment.
• Human Health advanced 5% organically, challenged by softness in North American dietary supplements but supported by strong early life nutrition and Advanced Health & Nutrition products.